Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Status and Forecast

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs. Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth. The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators. In 2018, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size was 5860 million US$ and it is expected to reach 11500 million US$ by the end of 2025, with a CAGR of 8.8% during 2019-2025. This report focuses on the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China. The key players covered in this study Astellas Inc. Johnson & Johnson Sanofi S.A Dendreon Corporation Bayer AG ... Market segment by Type, the product can be split into Oral Therapy Injectable Therapy Market segment by Application, split into Hospitals & Clinics Home Settings Ambulatory Surgical Centers (ASCs) Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America The study objectives of this report are: To analyze global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics status, future forecast, growth opportunity, key market and key players. To present the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions. In this study, the years considered to estimate the market size of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get sample copy of the report:

https://www.marketdensity.com/contact?ref=Sample&reportid=121523

Table of Contents:

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Oral Therapy
1.4.3 Injectable Therapy
1.5 Market by Application
1.5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals & Clinics
1.5.3 Home Settings
1.5.4 Ambulatory Surgical Centers (ASCs)
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size
2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Growth Trends by Regions
2.2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions (2014-2025)
2.2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Manufacturers
3.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Manufacturers (2014-2018)
3.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Manufacturers (2014-2018)
3.1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Area Served
3.3 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product/Solution/Service
3.4 Date of Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2014-2019)
4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
5.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in United States
5.3 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
5.4 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

6 Europe
6.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
6.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in Europe
6.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
6.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

7 China
7.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
7.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in China
7.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
7.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

8 Japan
8.1 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
8.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in Japan
8.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
8.4 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
9.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
9.4 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

10 India
10.1 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
10.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in India
10.3 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
10.4 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2014-2019)
11.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players in Central & South America
11.3 Central & South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
11.4 Central & South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application

12 International Players Profiles
12.1 Astellas Inc.
12.1.1 Astellas Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
12.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2014-2019)
12.1.5 Astellas Inc. Recent Development
12.2 Johnson & Johnson
12.2.1 Johnson & Johnson Company Details
12.2.2 Company Description and Business Overview
12.2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
12.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2014-2019)
12.2.5 Johnson & Johnson Recent Development
12.3 Sanofi S.A
12.3.1 Sanofi S.A Company Details
12.3.2 Company Description and Business Overview
12.3.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
12.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2014-2019)
12.3.5 Sanofi S.A Recent Development
12.4 Dendreon Corporation
12.4.1 Dendreon Corporation Company Details
12.4.2 Company Description and Business Overview
12.4.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
12.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2014-2019)
12.4.5 Dendreon Corporation Recent Development
12.5 Bayer AG
12.5.1 Bayer AG Company Details
12.5.2 Company Description and Business Overview
12.5.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
12.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2014-2019)
12.5.5 Bayer AG Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Browse this report online:

https://www.marketdensity.com/global-castration-resistant-prostate-cancer-crpchrpca-therapeutics-market-size-status-and-forecast

About Market Density:

Market Density is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage.
Market Density offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Market Density understands how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:

Email: sales@marketdensity.com

Website: www.marketdensity.com

Phone: +1 669 264 1656

4340 Stevens Creek Blvd,
Suite # 172,
San Jose, CA 95129

This release was published on openPR.